OLMA on Nasdaq

Olema Pharmaceuticals, Inc.

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerOLMA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Francisco, California1
  • Incorporated inDE2
  • Business address780 Brannan Street, San Francisco, Ca 941032
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$178.7M in 2025+4034% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$4.3M-$4.3M20192020: -$21.5M-$21.5M2020+398%2021: -$71.5M-$71.5M2021+232%2022: -$107.0M-$107.0M2022+50%2023: -$105.0M-$105.0M2023−2%2024: -$142.3M-$142.3M2024+36%2025: -$178.7M-$178.7M2025+26%
Net income45678-$162.5M in 2025+3664% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$4.3M-$4.3M20192020: -$22.1M-$22.1M2020+413%2021: -$71.1M-$71.1M2021+221%2022: -$104.8M-$104.8M2022+47%2023: -$96.7M-$96.7M2023−8%2024: -$129.5M-$129.5M2024+34%2025: -$162.5M-$162.5M2025+25%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$157.7M$124.5M
General and administrative$21.0M$17.7M
Total operating expenses$178.7M$142.3M
Loss from operations-$178.7M-$142.3M
Interest income$16.2M$12.7M
Other income$23.0K$102.0K
Total other income$16.2M$12.8M
Net loss-$162.5M-$129.5M
Net loss per share, basic (in dollars per share)-$1.87-$2.20
Net loss per share, diluted (in dollars per share)-$1.87-$2.20
Weighted average shares used to compute net loss per share, basic (in shares)87.0M shares58.7M shares
Weighted average shares used to compute net loss per share, diluted (in shares)87.0M shares58.7M shares
One-time milestone payments to Aurigene$10.0M$5.0M

Compare Olema Pharmaceuticals, Inc. with another company

Leadership

Who has led Olema Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Sean Bohen2020–now

President

  1. Sean Bohen2020–now

Chief financial officer

  1. Jason O'Byrne2026–now
2025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDavid C. Myles, Ph.D. named Sep 14, 2023 to Dec 12, 202433
  • Executive Officer, DirectorSean Bohen, M.D., Ph.D. named Sep 14, 2023 to Dec 12, 202433
  • DirectorCyrus L. Harmon, Ph.D. named Sep 14, 2023 to Dec 12, 202433
  • DirectorGorjan L. Hrustanovic, Ph.D. named Sep 14, 2023 to Dec 12, 202433
  • DirectorGraham L. Walmsley, M.D., Ph.D. named Sep 14, 2023 to Dec 12, 202433

Timeline

  1. Nov 18, 2020New chief executive Sean Bohen becomes CEO11

Filings

453 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 178 insider forms, 51 large holders, 2 private raises, 142 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 2, 20264 EDGAR
  3. Aug 13, 20263 EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Aug 10, 202610-Q EDGAR
  6. Aug 10, 20268-K EDGAR
  7. Aug 6, 2026SCHEDULE 13G/A EDGAR
  8. Jul 29, 2026SCHEDULE 13G/A EDGAR
  9. Jul 27, 20264 EDGAR
  10. Jul 24, 2026144 EDGAR
  11. Jul 23, 2026144 EDGAR
  12. Jun 23, 20264 EDGAR
  13. Jun 23, 20264 EDGAR
  14. Jun 23, 20264 EDGAR
  15. Jun 23, 20264 EDGAR
  16. Jun 23, 20264 EDGAR
  17. Jun 23, 20264 EDGAR
  18. Jun 23, 20264 EDGAR
  19. Jun 23, 20264 EDGAR
  20. Jun 23, 20264 EDGAR

The 453 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

95 open-market trades by officers, directors and large owners since October 2021: 12 buys and 83 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 24, 2026Harmon CyrusDirectorSale12,500$11.71$146.4KForm 4
Jul 23, 2026Harmon CyrusDirectorSale12,500$11.58$144.8KForm 4
Mar 4, 2026Mitchell ShawnteCHIEF LEGAL OFFICERSale25,000$24.25$606.4KForm 4
Mar 3, 2026Mitchell ShawnteCHIEF LEGAL OFFICERSale15,000$23.01$345.1KForm 4
Jan 20, 2026Harmon CyrusDirectorSale10,000$26.88$268.8KForm 4
Jan 15, 2026Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Sale100,000$28.73$2.9MForm 4
Jan 14, 2026Harmon CyrusDirectorSale3,489$29.12$101.6KForm 4
Jan 14, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale50,000$28.87$1.4MForm 4
Jan 13, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale50,000$27.60$1.4MForm 4
Jan 13, 2026Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Sale3,822$28.01$107.1KForm 4
Jan 12, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale10,000$28.34$283.4KForm 4
Dec 23, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale99,509$27.66$2.8MForm 4
Dec 22, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale100,000$28.04$2.8MForm 4
Dec 22, 2025Harmon CyrusDirectorSale2,881$28.53$82.2KForm 4
Dec 19, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale70,000$28.20$2.0MForm 4
Dec 19, 2025Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale51,000$30.46$1.6MForm 4
Dec 19, 2025CLARK IAN TDirectorSale264,800$29.73$7.9MForm 4
Sep 18, 2025Harmon CyrusDirectorSale13,086$8.33$109.0KForm 4
Sep 16, 2025Harmon CyrusDirectorSale11,914$8.05$95.9KForm 4
Jan 8, 2025Bain Capital Life Sciences Investors, LLC10% ownerBuy300,000$5.76$1.7MForm 4

All 95 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 4, 2024Raised $250 million in a private offering of equity Form D: $250 million offered in all Form D
  2. Sep 5, 2023Raised $130 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC12,143,062$151.9M0.0%+1,756,217
Paradigm Biocapital Advisors LP8,670,576$108.5M2.0%+650,000
Jupiter Topco LLC7,094,413$88.8M0.0%New
Bain Capital Life Sciences Investors, LLC7,085,249$88.6M5.3%−387,989
BlackRock, Inc.6,714,691$84.0M0.0%+1,062,556
Bvf Inc/il5,295,893$66.3M1.7%No change
Siren, L.L.C.4,856,949$60.8M1.2%+100,000
State Street Corp4,316,058$54.0M0.0%+378,227
Vanguard Capital Management LLC3,341,217$41.8M0.0%+257,700
Logos Global Management LP3,208,875$40.1M1.7%No change
Franklin Resources Inc2,349,586$29.4M0.0%+1,130,629
Cormorant Asset Management, LP2,150,000$26.9M1.4%−1,750,000
Morgan Stanley1,832,269$22.9M0.0%+616,579
Geode Capital Management, LLC1,819,029$22.8M0.0%+274,612
Vanguard Portfolio Management LLC1,663,218$20.8M0.0%+1,070,187
Goldman Sachs Group Inc1,567,979$19.6M0.0%+522,390
Deep Track Capital, LP1,500,000$18.8M0.3%New
Dimensional Fund Advisors LP1,416,533$17.7M0.0%+334,099
Lightspeed Management Company, L.l.c.1,355,299$17.0M0.7%No change
Kingdon Capital Management, L.l.c.1,200,000$15.0M2.0%+345,000
Two Sigma Investments, LP1,131,434$14.2M0.0%−37,987
Point72 Asset Management, L.P.1,070,949$13.4M0.0%+999,842
Defilade Capital Management, L.P.924,758$11.6M1.5%−579,778
Ameriprise Financial Inc840,646$10.5M0.0%+783,284
Woodline Partners LP751,030$9.4M0.0%−731,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49